The main problem in the follow-up of patients receiving organ allografts is the early differential diagnosis of rejection episodes and infections. Serum levels of interferon gamma, a marker of T-lymphocyte activity, were determined with an immunoradiometric assay, specific for biologically active interferon gamma and sufficiently sensitive (20 Ü/l) for the determination of circulating interferon gamma. Neopterin, a pteridine released from stimulated macrophages, was determined by radioimmunoassay. Both rejection crises and infections are accompanied by distinct increases of serum neopterin (median values 124 and 128nmol/l; N == 98). Interferon gamma levels are elevated for a short period one or two days earlier, the maximal values during infections (median 430 U/l, ränge 120 -1220 U/l, N = 25) being higher than those during rejection episodes (median 120 U/l, ränge < 20 -330 U/l, N = 73). Each rise of interferon gamma was followed by an increase of neopterin, but not every neopterin increase was preceded by a interferon gamma peak. Neither of these parameters showed an increase during deterioratiön of kidney function due to cyclosporin toxicity. The determination of interferon gamma, a lymphokine involved in the activation of alloreactivity, reflecting T-cell Stimulation, and the measurement of neopterin, a secretory product of activated macrophages, allows the simple, quick and reliable monitoring of the immune Status of transplant recipients.
Introduction
Immunological monitoring of patients with heart or kidney allografts is decisive for the proper treatment of possible complications. Despite significant improvements in the clinical management of transplant recipients, with reduction of the corticosteroid dosage and immunosuppression with cyclosporin A, differential diagnosis of infections and rejections still poses a major problem. This distinction is especially critical, because the necessary subsequent changes in the immunosuppressive regimen are different, depending on the diagnosis. It has been shown that low excretion of neopterin in urine is a reliable indicator for the absence of immunological Stimuli, whereas high excretion is found during rejection episodes and infections (1) . In vitro interferon gamma, a lymphokine secreted by activated T-cells, stimulates the release of neopterin from macrophages (2) . We report here the results of measurements in patient sera of interferon gamma and neopterin, and demonstrate that a similar regulatory pattern does exist in vivo. The routine determinations of neopterin and interferon gamma seem to be of high relevance for the daily monitoring of transplant recipients.
Methods
Interferon gamma was determined using a modified Version of a commercially available immunoradiometric assay (3). In this 2-step "sandwich" test interferon gamma present in the sample is fürst bound to a monoclonal antibody coated onto a polystyrene bead. In the second Step, the bound interferon gamma in turn binds to another monoclonal antibody, labelled with iodine-125. One of the two antibodies is specific for the active structure, thus measuring only biologically active interferon gamma with a sensitivity of 20 U/l.
Neopterin in serum was determined with a radioimmunosassay (Henning, Berlin, FRG; (4)), modified to adapt its working ränge to the elevated levels expected in transplant patients: The sample volume was reduced from 50 to 20 and an additional Standard (320 nmol/1) was used for the construction of the Standard curve. The incubation and Separation Steps were äs recommended in the instructions for use.
Patients
In six patients with heart transplants, serum levels of interferon gamma and neopterin were determined throughout the early postoperative period of at least 5 weeks. In 63 patients with kidney transplants (age IS-62 years), seruni levels of neopterin were determined daily. The main reasons for kidney failure were chronic glomerulonephritis, chronic pyelonephritis, polycystic kidney disease and interstitial nephritis. In 28 of these patients interferon gamma was measured daily. Six heart recipients (age 10-40 years) were transplanted due to cardiomyopathy, coronary heart disease or intractably reduced ventricle function. Sample collection started on the day of transplantatipn and was continued until discharge from the unit. The hnmunosuppressive therapy consisted of cyclosporin A and prednisolone in the majority of kidney patients, whereas according to the Standard protocol all the heart patients received azathioprine and anti-thymocyte globulin. In rejection cases, pulse therapy with high-dose methylprednisolone and repeated anti-thymocyte globulin was performed (tab. 1). Diagnosis of rejection in kidney recipients was based on clinical Symptoms, laboratory fmdings, blood chemistry, sonography and the 111-Indiumlabelled platelet uptake index. In heart transplant patients diag-. nosis of rejection was based mainly on endoniyocardial biopsy (5), whereas other methods such äs echocardiography and ECG were not of decisive importance. Heart biopsies were taken weekly, in cases of clinical impairment and after treatment by steroid pulse therapy. In kidney patients, biopsies were taken if necessary and analysed cytologically (fine needle aspiration biopsy) or histologically (tru-eut biopsy). 99m-Technetium bolus investigation, computerized tomography, and digital subtraction angiogräphy were performed, äs appropriatC; The diagnosis of complicating infections was based on repeated bacteriological and serological tests such äs blöod cultures, complement binding reaction, IgM-and IgG-titers, and virus Isolation in addition to clinical : ,symptoms.
Changes in serum neopterin were evaluated statistically, using Studenfs t-difference test. Since data were not normally distributed, median values and ranges are given. Differences between groups were calculated using a non-parametric test.
Results
Serum neopterin levels were significantiy different depending upon the clinical course after transplantation ( fig. 1 ). Thirty five kidney graft recipients without infections were classified into 3 groups according to their clinical course. All were treated only with cyclosporin A and steroids and/or anti-thymocyte globulin (tab. 1), and none of these patients suffered from severe infections that might have influê nced serum neopterin levels or required modifications in the immunsuppressive management during the early postoperative period of up to 5 weeks.
Group I comprised 8 patients free of immunological complications, and therefore without additional immunosuppressive therapy. Neopterin decreased ra- pidly to levels only slightly higher than those of healthy normal controls (N = 25).
Twenty two patients (group II) had rejection episodes diagnosed by cliniqal Symptoms or transplant biopsy that were reversible by appropriate therapy. A decrease of neopterin values was also observed, but was delayed in comparison with group I. On the day of discharge, neopterin levels were slightly, but not significantly higher than for group I.
Group III comprises the five patients that lost their transplants due to irreversible rejection. The highest neopterin values were found on the day before graft loss. Figure 2 shows similar, but individual data for six heart transplant patients. To Interpret the pretransplant levels of neopterin in serum, values for patients with chronic renal failure and the effects of haemodialysis are shown in figure 3 . After dialysis, concentrations of neopterin were decreased by about 50%, but they were still 5-fold higher than normal controls. No quantitative correlation between the reduction by haemodialysis of senim neopterin and creatinine, blood urea nitrogen or uric acid was found. Data from patients with rejections and infectious complications are summarized in table 2. In all patients with severe infection episodes (viral, N = 8, and bacterial, N = 17) distinct peaks of Interferon gamma were observed, followed l to 2 days later by marked increases of neopterin. In contrast, less pronounced or unmeasurable increments of interferon gamma were seen during acute rejection episodes, whereas neopterin peak levels were äs high äs those during infections. To ilhzstrate the relation between neopterin and interferon gamma in serum, four cases are showü in figures 4 a-d (details are given in the legends).
Discussion
The clinical value of daily measurements of neopterin excretion in urine has been demonstrated in kidney transplantations and other clinical situations (1). Recently, it has been shöwn that the neopterin is released by maerophages when they are stimulated by interferon gamma produced from activated T-lymphocytes (2) . These in vitro results have prompted us to investigate the use of serum neopterin for the monitoring of transplant patients and to search för a similar regulatory pattern in vivo. Case reports have been published (5) in which measurable interferon gamma levels in serum were found associated with stimulations of the immune System, ! both during infections and in some but not all rejection crises. A clinically uiicomplicated posttransplant course was almost invariably associated with rapidly decreasing neopterin levels in kidney patients and with stable and low levels for heart recipients. This dissimilarity is probably the consequence of different pretransplant levels. Patients on haemodialysis have neopterin values much higher than normal controls even without any apparent immunological Stimuli, reflecting the predominantly renal excretion of pteridines. The onset of acute rejection episodes were in all cases associated with rising neopterin levels or, in the case of some kidney recipients, with delay or cessation of the decline expected for an immunologically uncomplicated course. The relative small increase of neopterin in the heart patient with an irreversible rejection is probably due to the early end of function of this vital organ, which contrasts with rejection episodes in kidney recipients that are not of immediate danger to life. Interferon gamma was clearly elevated for a short period at the onset of infections, but only to a lower extent during rejection crises. It thus appears that the daily monitoring of interferon gamma and neopterin levels in serum are useful for the detection of immunological activations. Similarly, urinary neopterin excretion has been shown to allow the early diagnosis of acute rejections and viral infections with very few false positive results (1).
With the development of a quick and reliable assay sufficiently sensitive to detect interferon gamma in peripheral blood, it is now possible to determine a lymphokine that controls the activation of maerophages. This offers an additional advantage, since elevations of interferon gamma preceeded the neopterin increases by one or two days, äs expected • from in vitro experiments. Without exception, every increase of interferon gamma over 120 U/l was followed by a significant rise in neopterin. From a practical point of view its determination in serum seems to be at least äs useful äs the determination of the urinary excretion, with the additional advantage of being independent of urine output. Furthermore, interferon gamma might help in the differential diagnosis of rejection and infection, since the majority of infections showed peak levels above the maximal values measured during acute rejections.
In conclusion, the simultaneous daily determination of interferon gamma and neopterin in the early postoperative period seems to be a useful tool for differential diagnosis of immunological complications and for monitoring their treatment in kidney and heart transplant patients.
